Bayer’s Asundexian Reduces Recurrent Stroke Risk by 26 Percent in Landmark Phase III Trial

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...

February 10, 2026 | Tuesday | News
Bristol Myers Squibb Partners with Evinova to Advance AI Driven Clinical Trial Optimization

Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency ...

February 10, 2026 | Tuesday | News
Median Technologies Secures FDA Clearance for AI Powered eyonis LCS Lung Cancer Screening Software

eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unne...

February 10, 2026 | Tuesday | News
Peijia Medical Advances Global Expansion with EU MDR CE Mark Filing for GeminiOne TEER System

Peijia Medical Limited announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application fo...

February 10, 2026 | Tuesday | News
Eisai’s Leqembi Autoinjector Clears Key Regulatory Step in China for Early Alzheimer’s Treatment

BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced  that the Biologics License Application (BLA) for the treatme...

February 10, 2026 | Tuesday | News
Genentech Advances Regulatory Path for Fenebrutinib After Phase III Success in Progressive MS

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...

February 09, 2026 | Monday | News
Ascentage Pharma Strengthens Hematologic Cancer Pipeline with Global Clinical Advancement of APG-3288

Ascentage Pharma Group International , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commerc...

February 09, 2026 | Monday | News
Aminex Launches Mid-Stage Trial of Polyamine-Targeting Therapy in Solid Tumors

Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system  Aminex Therapeutics, Inc., a...

February 06, 2026 | Friday | News
10x Genomics Powers UK PharosAI Initiative to Build Multimodal Cancer Dataset

Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel p...

February 06, 2026 | Friday | News
SEQSTER and Praxis Expand Collaboration to Accelerate CNS Clinical Development

Multi-study collaboration leverages SEQSTER's real world data (RWD) platform to support Praxis's portfolio of precision therapies for CNS disorders ...

February 04, 2026 | Wednesday | News
Acadia Signals Re-Examination Path After Negative CHMP Trend Vote for Trofinetide

Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoptio...

February 04, 2026 | Wednesday | News
H.U. Group’s Fujirebio Launches Fully Automated pTau217 CSF Assay for Alzheimer’s Research

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automat...

January 30, 2026 | Friday | News
Elevar Submits NDA for Lirafugratinib as Second-Line FGFR2-Driven Cholangiocarcinoma Therapy

  Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...

January 30, 2026 | Friday | News
Ernexa Therapeutics Selected for Japan Entry Acceleration Program, Joining Elite Group of Global Cell Therapy Innovators

Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...

January 29, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close